There are 37 Parkinson drugs under development in the United States

According to the latest industry data, there are currently 37 new drugs for Parkinson's disease being developed by American Biopharmaceuticals, of which 23 are for the treatment of the disease, 11 are for related symptoms, and 3 are diagnostic reagents. According to a report from PHRMA, all 23 new products are currently in clinical trials or FDA reviews.

About 10 million people worldwide suffer from this chronic and progressive neurological disease, including as many as 1.5 million people in the United States. There are approximately 600,000 new cases each year. This figure does not reflect more untested cases. It is predicted that if the intervention measures do not change, the prevalence of Parkinson's disease will be more than three times that of the current period by 2040. PHRMA said.

The latest report lists a series of methods used to treat and treat this disease. These include:

Gene therapy drugs that contain an adeno-associated virus (AAV) vector that can deliver the aromatic amino acid decarboxylase (AADC) gene to parts of the brain that control movement;

A potential first-line drug that targets a receptor in the brain that is often abnormal in the brains of people with Parkinson's disease;

A molecular imaging agent that assists in the diagnosis of Parkinson's disease through single-photon emission computed tomography (SPECT);

A potential first-line treatment for Parkinson's disease disorders (PDP);

New delivery mechanisms include a nasal formulation and an intestinal gel.

The PHRMA report also reviewed the economic impact of Parkinson's disease. In the United States alone, it is estimated that at least 14.4 billion U.S. dollars will be spent each year, 8.1 billion U.S. dollars will be spent on medical treatment, and 6.3 In the United States, people with Parkinson's disease suffer an average of $22,800 per person per year in the cost associated with the disease. This figure is $12,800 higher than the number of people who do not have this disease. Predictions indicate that if the disease process can be slowed by 50%, it will be reduced. 35% extra cost, PhRMA reported.

"The economic burden of Parkinson's disease and the demand for services and support are growing exponentially as the world's population ages. More cooperation will better help meet the needs of people with Parkinson's disease and allow us to continue to deal with this global Public health challenges." PhRMACEOJohnJ Castellani said.